CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 49 enrolled
Drug / intervention
Prednisolone and/or AZA/MMF +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04870359
NCT04870359N/ACompleted
CompareCT.gov

Pre-emptive Increase of Immunosuppressive Treatments in Lupus Nephritis Patients With Asymptomatic Serological Reactivation

The University of Hong Kong·interventional·Posted May 3, 2021·Updated Dec 16, 2024

In Brief

A clinical study evaluating Pre-emptive increase of immunosuppressive treatments and Prednisolone and/or AZA/MMF for Lupus Nephritis. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who experienced ASR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis
CountriesHong Kong
CollaboratorsUnited Christian Hospital

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 3, 2021
Enrollment StartApr 21, 2016
Primary CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 5.2 years ago

Interventions

Pre-emptive increase of immunosuppressive treatmentsprocedure

1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks. 2. Adjustment of the 2nd agent would be as follows: 1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day. 2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day.

Prednisolone and/or AZA/MMFdrug

Prednisolone and/or AZA/MMF